PortalPublikationenFirst description of a hybrid tumor of the sublingual gland

First description of a hybrid tumor of the sublingual gland

Standard

First description of a hybrid tumor of the sublingual gland. / Eichhorn, Wolfgang; Precht, Clarissa; Wehrmann, Manfred; Hickmann, Elisabeth; Eichhorn, Marc; Zeuch, Jürgen; Löning, Thomas; Friedrich, Reinhard E; Heiland, Max; Hoffmann, Jürgen.

in: ANTICANCER RES, Jahrgang 33, Nr. 10, 01.10.2013, S. 4567-71.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Eichhorn, W, Precht, C, Wehrmann, M, Hickmann, E, Eichhorn, M, Zeuch, J, Löning, T, Friedrich, RE, Heiland, M & Hoffmann, J 2013, 'First description of a hybrid tumor of the sublingual gland', ANTICANCER RES, Jg. 33, Nr. 10, S. 4567-71.

APA

Eichhorn, W., Precht, C., Wehrmann, M., Hickmann, E., Eichhorn, M., Zeuch, J., Löning, T., Friedrich, R. E., Heiland, M., & Hoffmann, J. (2013). First description of a hybrid tumor of the sublingual gland. ANTICANCER RES, 33(10), 4567-71.

Vancouver

Eichhorn W, Precht C, Wehrmann M, Hickmann E, Eichhorn M, Zeuch J et al. First description of a hybrid tumor of the sublingual gland. ANTICANCER RES. 2013 Okt 1;33(10):4567-71.

Bibtex

@article{be632990a19d4ae28c6adeec0abc7866,
title = "First description of a hybrid tumor of the sublingual gland",
abstract = "BACKGROUND: Hybrid tumours of the salivary glands are rare neoplasms. They are composed of at least two different tumour entities located in the same topographic area and account for only 0.1% of all salivary gland tumours. The most common component is an adenoid cystic carcinoma. There are several possible forms of hybrid tumours, which are most commonly located in the parotid gland. Case Report: We report on a 59-year-old female, who presented with a lesion of the caruncula of the left sublingual gland. The biopsy showed an adenoid cystic carcinoma in combination with a salivary duct carcinoma. Treatment consisted of tumour resection, bilateral selective neck dissection and adjuvant radiotherapy. Histopathologically, at least 30% of the tumour mass was composed of a salivary duct carcinoma and 70% of an adenoid cystic carcinoma. At 58 months after treatment, the patient is alive without evidence of recurrent disease.CONCLUSION: To our knowledge, the presented case is the first description of a hybrid tumour of the sublingual gland. Furthermore, the post-therapeutic course is encouraging, as hybrid tumours of the salivary glands usually have a poor prognosis.",
keywords = "Carcinoma, Adenoid Cystic, Carcinoma, Ductal, Female, Humans, Middle Aged, Neoplasms, Complex and Mixed, Sublingual Gland Neoplasms, Treatment Outcome",
author = "Wolfgang Eichhorn and Clarissa Precht and Manfred Wehrmann and Elisabeth Hickmann and Marc Eichhorn and J{\"u}rgen Zeuch and Thomas L{\"o}ning and Friedrich, {Reinhard E} and Max Heiland and J{\"u}rgen Hoffmann",
year = "2013",
month = oct,
day = "1",
language = "English",
volume = "33",
pages = "4567--71",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

RIS

TY - JOUR

T1 - First description of a hybrid tumor of the sublingual gland

AU - Eichhorn, Wolfgang

AU - Precht, Clarissa

AU - Wehrmann, Manfred

AU - Hickmann, Elisabeth

AU - Eichhorn, Marc

AU - Zeuch, Jürgen

AU - Löning, Thomas

AU - Friedrich, Reinhard E

AU - Heiland, Max

AU - Hoffmann, Jürgen

PY - 2013/10/1

Y1 - 2013/10/1

N2 - BACKGROUND: Hybrid tumours of the salivary glands are rare neoplasms. They are composed of at least two different tumour entities located in the same topographic area and account for only 0.1% of all salivary gland tumours. The most common component is an adenoid cystic carcinoma. There are several possible forms of hybrid tumours, which are most commonly located in the parotid gland. Case Report: We report on a 59-year-old female, who presented with a lesion of the caruncula of the left sublingual gland. The biopsy showed an adenoid cystic carcinoma in combination with a salivary duct carcinoma. Treatment consisted of tumour resection, bilateral selective neck dissection and adjuvant radiotherapy. Histopathologically, at least 30% of the tumour mass was composed of a salivary duct carcinoma and 70% of an adenoid cystic carcinoma. At 58 months after treatment, the patient is alive without evidence of recurrent disease.CONCLUSION: To our knowledge, the presented case is the first description of a hybrid tumour of the sublingual gland. Furthermore, the post-therapeutic course is encouraging, as hybrid tumours of the salivary glands usually have a poor prognosis.

AB - BACKGROUND: Hybrid tumours of the salivary glands are rare neoplasms. They are composed of at least two different tumour entities located in the same topographic area and account for only 0.1% of all salivary gland tumours. The most common component is an adenoid cystic carcinoma. There are several possible forms of hybrid tumours, which are most commonly located in the parotid gland. Case Report: We report on a 59-year-old female, who presented with a lesion of the caruncula of the left sublingual gland. The biopsy showed an adenoid cystic carcinoma in combination with a salivary duct carcinoma. Treatment consisted of tumour resection, bilateral selective neck dissection and adjuvant radiotherapy. Histopathologically, at least 30% of the tumour mass was composed of a salivary duct carcinoma and 70% of an adenoid cystic carcinoma. At 58 months after treatment, the patient is alive without evidence of recurrent disease.CONCLUSION: To our knowledge, the presented case is the first description of a hybrid tumour of the sublingual gland. Furthermore, the post-therapeutic course is encouraging, as hybrid tumours of the salivary glands usually have a poor prognosis.

KW - Carcinoma, Adenoid Cystic

KW - Carcinoma, Ductal

KW - Female

KW - Humans

KW - Middle Aged

KW - Neoplasms, Complex and Mixed

KW - Sublingual Gland Neoplasms

KW - Treatment Outcome

M3 - SCORING: Journal article

C2 - 24123032

VL - 33

SP - 4567

EP - 4571

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 10

ER -